Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlumosbart (JMT103) in bone metastases from solid tumors
NCT04630522Phase 1Completed
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of narlumosbart in bone metastases (3 arms), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Percentage change of urinary N-terminal telopeptide of type 1 collagen/creatine at Week 13. Started Oct 2020; status: completed.
02
Drugs
narlumosbart
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT04630522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630522.